Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.44 |
| ▸ | PPARD | Q03181 | 4/20 | 0.44 |
| ▸ | PPARA | Q07869 | 3/20 | 0.44 |
| ▸ | ACACB | O00763 | 3/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | EPOR | P19235 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26239233 | 0.83 | KCNH2 (0.55) | L3MBTL1 | |
| SCHEMBL24600935 | 0.82 | SMN1; SMN2 (0.51) | PPARGPPARDPPARALTA4HALDH1A1 | |
| SCHEMBL26239239 | 0.79 | KCNH2 (0.54) | PPARGPPARDPPARASMN1; SMN2 | |
| SCHEMBL10329633 | 0.77 | ESR1 (0.41) | PPARGPPARDPPARALTA4HEPOR | |
| SCHEMBL7340054 | 0.73 | ITGB3 (0.49) | ACACBSMN1; SMN2 | |
| SCHEMBL2476605 | 0.73 | KDM4E (0.49) | LTA4HKEAP1NFE2L2ALDH1A1SMN1; SMN2 | |
| SCHEMBL7281578 | 0.73 | EPOR (0.54) | LTA4HEPORALDH1A1L3MBTL1MEN1 | |
| SCHEMBL2059173 | 0.72 | HRH3 (0.52) | PPARGPPARDPPARALTA4HKEAP1 | |
| SCHEMBL8510027 | 0.72 | TDP1 (0.58) | LTA4HKEAP1NFE2L2ALDH1A1SMN1; SMN2 | |
| SCHEMBL16682339 | 0.71 | TDP1 (0.45) | LTA4HKEAP1NFE2L2SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025846-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | ACAD PHARMACEUTICALS INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11731938-B2 | Ultra short acting anti-arrhythmic agents | ACADEMIC PHARMACEUTICALS INC (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731938-B2 | Ultra short acting anti-arrhythmic agents | CACNA1G, SCN5A, CACNA1F | PPARG 2019/4885PPARD 904/4885PPARA 1849/4885 |
| US-20240025846-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | CACNA1G, SCN5A, CACNA1F | PPARG 2019/4885PPARD 904/4885PPARA 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.